Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T15:47:21.830Z.
Calculation as of: 2026-10-06T15:47:21.830Z.
Quote observation: 2026-10-06T15:45:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 880fb47a961da82dee7b372bf013e19f9356fddf046c7e26e64914405e113cb3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Lexeo Therapeutics, Inc. Common Stock
Market Cap
$265.01M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$265.39M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$268.87M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$262.97M
EV/EBITDA Ratio
N/A
TTM Avg
128764.90x
3Y Avg
128764.90x
5Y Avg
128764.90x
Market Cap
$268.17M
EV/EBITDA Ratio
N/A
TTM Avg
2.41x
3Y Avg
3817.71x
5Y Avg
2177.76x
Market Cap
$258.32M
EV/EBITDA Ratio
477.84x
TTM Avg
197.45x
3Y Avg
157.93x
5Y Avg
101.85x
Market Cap
$269.13M
EV/EBITDA Ratio
N/A
TTM Avg
10.21x
3Y Avg
10.21x
5Y Avg
10.68x
Market Cap
$254.41M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lexeo Therapeutics, Inc. Common Stock (LXEO) | $265.01M | N/A | N/A | N/A | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $265.39M | N/A | N/A | N/A | N/A |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $268.87M | N/A | N/A | N/A | N/A |
| Palisade Bio, Inc. (PALI)vs › | $262.97M | N/A | 128764.90x | 128764.90x | 128764.90x |
| OraSure Technologies, Inc. (OSUR)vs › | $268.17M | N/A | 2.41x | 3817.71x | 2177.76x |
| Anika Therapeutics, Inc. (ANIK)vs › | $258.32M | 477.84x | 197.45x | 157.93x | 101.85x |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $269.13M | N/A | 10.21x | 10.21x | 10.68x |
| AC Immune S.A. (ACIU)vs › | $257.49M | N/A | 15.20x | 12.43x | 15.17x |
| Century Therapeutics, Inc. (IPSC)vs › | $254.41M | N/A | N/A | N/A | N/A |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $276.08M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
